A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function

Inclusion Criteria:

• Patients having histologically-proven solid tumors, who are either refractory to standard chemotherapy;
• Patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate;
• Creatinine clearance according to Cockcroft-Gault formula : Normal > 80 mL/min, Mild 50-80 mL/min, Moderate 30-<50 mL/min;
• A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies;
• Potassium, calcium, magnesium and phosphorus values within the normal range;
• Body Mass Index (BMI) must be within the range of 18 and 30

Exclusion Criteria:

• Patients having CNS metastases, must have a CT or MRI of the brain performed to rule out CNS metastases;
• Patients with leptomeningeal disease metastases;
• Radiotherapy </- weeks prior to starting study drug;
• Major surgery </ 4 weeks prior to the start of study;
• Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14 days prior to starting study drug;

Other protocol-defined inclusion/exclusion criteria may apply